These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 28221220)
1. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Eapen RS; Herlemann A; Washington SL; Cooperberg MR Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220 [TBL] [Abstract][Full Text] [Related]
2. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017 [TBL] [Abstract][Full Text] [Related]
3. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117 [TBL] [Abstract][Full Text] [Related]
4. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383 [TBL] [Abstract][Full Text] [Related]
5. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia. Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454 [TBL] [Abstract][Full Text] [Related]
6. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Fleshner K; Carlsson SV; Roobol MJ Nat Rev Urol; 2017 Jan; 14(1):26-37. PubMed ID: 27995937 [TBL] [Abstract][Full Text] [Related]
7. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation. Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680 [TBL] [Abstract][Full Text] [Related]
8. What's new in screening in 2015? Carlsson SV; Roobol MJ Curr Opin Urol; 2016 Sep; 26(5):447-58. PubMed ID: 27326657 [TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Moyer VA; Ann Intern Med; 2012 Jul; 157(2):120-34. PubMed ID: 22801674 [TBL] [Abstract][Full Text] [Related]
10. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications. Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328 [TBL] [Abstract][Full Text] [Related]
11. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. Drazer MW; Huo D; Eggener SE J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181 [TBL] [Abstract][Full Text] [Related]
12. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update. Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579 [TBL] [Abstract][Full Text] [Related]
13. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057 [TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening. Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025 [TBL] [Abstract][Full Text] [Related]
15. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening. Joshi SS; Filson CP Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066 [No Abstract] [Full Text] [Related]
16. Prostate cancer screening practices in a large, integrated health system: 2007-2014. Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034 [TBL] [Abstract][Full Text] [Related]
17. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality. Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008 [TBL] [Abstract][Full Text] [Related]
18. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061 [TBL] [Abstract][Full Text] [Related]
19. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices. Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819 [TBL] [Abstract][Full Text] [Related]
20. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations. Li J; Berkowitz Z; Hall IJ J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]